REGMEDXB
FROM CARE TO CURE

Impact Report 2025



About RegMed XB

RegMed XB is a translational research and valorisation platform that brings together academic, industrial, governmental and health foundation partners in the Netherlands and Flanders to advance the field of regenerative medicine.

For patients

Affordable regenerative medicine solutions for chronic diseases.

For society

A competitive and sustainable regenerative medicine industry.

RegMed XB's offices are based in:

Utrecht

Leuven

Maastricht

Expanding the Ecosystem in 2025

Thematic Tech Transfer (TTT) programme

Dutch CardioVascular Alliance
First.
BGV.
Diabetes Fonds
Hersen Stichting
Hartstichting
NIER Stichting



Public-Private Partnerships (PPP)

Health Holland

Diabetes Moonshot INSPIRE Project:

Diabetes Fonds
don
Maastricht University
Leiden University Medical Center
HCM Medical
veldlaser
Medace
SCINUS CELL EXPANSION
COMATE Engineering & Design
QUALITY ASSISTANCE Contract Research Organisation

Osteoarthritis Moonshot SPARC Project:

Leiden University Medical Center
TU/e Eindhoven University of Technology
UMC Utrecht
Maastricht University
NecstGen
ICAT
ReGEN Biomedical
SBMC
SCINUS CELL EXPANSION
Rousselot by Darling Ingredients
LifeTec Group

*7 Dutch Collaboration

In Life Sciences & Health with National Growth Fund (Nationaal Groeifonds) initiatives.

This project is supported by the National Growth fund

HOLOmicrobiome
NXT GEN hightech
biotech booster
health RI
Oncode Accelerator
PharmaNL
Ombion Centre for Animal-free Biomedical Translation

Strengthening the Flemish–Dutch Advanced Therapy Medicinal Products (ATMPs) ecosystem

Interreg Vlaanderen-Nederland
Gefinancierd door de Europese Unie

ATMP XB

A selection of our partners is shown above; the full list can be found on page 12.

Ecosystem Highlights

Flanders

- New Leuven workspace
- ATMP XB collaboration

RegMed XB's Annual Conference

- 200 attendees
- 25+ SME exhibitors
- First cross-border edition in Flanders

Policy Engagement

- With national innovation partners
- Joint response on ATMP legislation

Dutch Collaboration

- With seven National Growth Fund initiatives:
  - Biotech Booster
  - Health-RI
  - Holomicrobiome
  - NXTGEN
  - Ombion
  - Oncode Accelerator
  - PharmaNL

Government of the Netherlands | This project is supported by the National Growth fund

Thematic Technology Transfer (TTT) programme and First Fund

- 2025-2030 programme €10 million awarded.
- 2020-2025 programme concluded.
  - 42 vouchers awarded
  - 13 start-ups supported
  - 7 investments completed
  - €5.47 million committed
  - >70% from TTT pipeline
  - Portfolio companies raised €61.6 million third-party funding (31-12-'25)

Netherlands Enterprise Agency

First.

Public-Private Partnerships (PPP)

€2 million allocated in 2025 for two Moonshot projects:

- Diabetes Moonshot (INSPIRE)
  €1.02 million, with 10 partners, 3 years
- Osteoarthritis Moonshot (SPARC)
  €0.98 million, with 11 partners, 2 years

Health Holland

Moonshot Highlights

Cardiovascular

Donor heart kept evaluable for 24 hours
Perfusion conditions of the ex vivo heart bioreactor were optimized so a donor heart stays in evaluable condition for a consistent 24 hours, with 48 hours in reach.

Biomarker panel validated
Biomarkers of endothelial dysfunction, cardiomyocyte stress, inflammation and coagulation were validated, supporting tissue assessment and therapeutic decision-making.

Diabetes

Novel islet purification method at LUMC
A new purification method for stem cell-derived insulin-producing islets sharply improves product purity and reduces unwanted cell types, strengthening safety and regulatory acceptability.

Delivery device selected, safety testing underway
An open-structure device design was chosen and preclinical safety testing by an external private partner is running, with final reports for the regulatory dossier due in 2026.

Eye

Efficient corneal endothelial cell production Researchers developed a highly efficient method for producing corneal endothelial cells, including a functional quality control assay for the cells.

Biomaterial membrane moves to the Pilot Factory Development of the biomaterial membrane progressed, with production transferring to the Smart BioMaterials Center in early 2026 ahead of pre-clinical safety and efficacy work.

Kidney

Functional donor-derived tubuloids on a chip Donor-derived kidney tubuloids were grown on a chip, replicating human distal tubular function and allowing precise assessment of water and sodium transport and drug and toxin responses.

Route to commercialisation with Mimetas
UMC Utrecht, Mimetas and the Kidney Foundation are advancing this animal-free model towards commercialisation, with regenerative interventions to be integrated from 2026.

Osteoarthritis

Strategic roadmap completed
A strategic roadmap set the phased pathway for a tissue-engineered ATMP for deep osteochondral defects, with the Target Product Profile scheduled for finalisation in 2026.

GMP cartilage cells produced in Flanders
The Flanders team achieved GMP production of primary human articular cartilage cells as building blocks for large osteochondral implants, ahead of cartilage patches in 2026.

Pilot Factory Highlights

State-of-the-art facilities — cleanrooms and pilot lines open to partners

Embedded expertise — technical and regulatory support on site

Scale-up platform — accelerating translation and manufacturing

Smart BioMaterials Center
Eindhoven

The pilot production site on the High Tech Campus was delivered and welcomed its first customer — the step from construction project to operating pilot factory. Four new cleanrooms totalling 400 m² opened for GMP production pipelines.

Innovation Center for Advanced Therapies
Utrecht

ICAT signed a contract with PlusUltra and made further progress on the construction of its new production facility. Alongside the build-out, activity in the innovation lab continued to grow, including a three-day Organ-on-a-Chip masterclass.

ReGEN Biomedical
Maastricht

At the ReGEN test centre a partial proof-of-concept setup was realised for the next generation ('Gen 2') of equipment — an early but concrete step toward the centre's future capabilities. ReGEN also joined the funded NEOLIVER and micro2MACRO consortia.

NecstGen
Leiden

The genetically modified hiPSC toolbox was expanded, and NecstGen supports the GMP transition and scale-up of stem cell-derived insulin-producing cells for the Diabetes Moonshot. It also joined the IPCEI Med4Health consortium on cost-effective production.

LUMC
Leiden

Concrete progress was made on automating the facility at LUMC's iPSC & Organ-on-Chip Hotel, strengthening reproducible cell production for the Moonshot programmes.

International Cooperation in 2025



BELGIUM

Annual Conference, Leuven

Science for Health, Brussels

Interreg, ATMP XB

SWEDEN

ATMP Roundtable at the Embassy of the Kingdom of the Netherlands in Sweden

ATMP Sweden session

MUNICH, GERMANY

BayOConnect, Partner Country Evening Impulse with Health Holland

BOSTON, USA

Innovation Mission to Massachusetts by the Netherlands Innovation network and the Netherlands Enterprise Agency

PARIS, FRANCE

Collaboration agreement INSERM

SWITZERLAND

Exploring bio-tech innovation in Basel, organised by Netherlands Enterprise Agency

OSAKA, JAPAN

Collaboration agreement with Nakanoshima Qross (2024)

World Expo Osaka

Life Sciences & Health Mission

Satellite office

Visit Nakanoshima Qross with a delegation to the Netherlands

Funding 2025

The Stichting RegMed XB is mainly funded through partner contribution, provincial funding, and various national government subsidy schemes, including the National Growth Fund.

1 Partner contribution

Three year commitment 2026–2028: Office funding plus co-funding of Moonshots, from academic partners, health foundations and WEWIS Flanders.

2 Provincial funding

Three year commitment 2025–2027.

3 RegMed XB Pilot Factory

Eight-year commitment 2021–2028.
€1.4 million of the €56.3 million NGF subsidy is for project coordination by the Office.



For patients: affordable regenerative medicine solutions for chronic diseases.
For society: a competitive and sustainable regenerative medicine industry.

Ecosystem overview

These programmes sit outside the Office's stand-alone annual accounts and show the broader resources mobilised across the RegMed XB regenerative medicine ecosystem.

Health Holland PPP programme

Public-private partnerships for health innovation.

€2 million allocated in 2025 for two Moonshot projects:

- Diabetes (INSPIRE)
  €1.02 million, 10 partners, 3 years
- Osteoarthritis (SPARC)
  €0.98 million, 11 partners, 2 years

TTT Valorisation programme

Translational acceleration and innovation.

- €10 million for new TTT programme 2025-2030 awarded.

RegMed XB's Pilot Factory

National Pilot Factory infrastructure scale-up.
Our pilot lines drive manufacturing readiness across the ecosystem, and are involved in the Moonshots.

Office 2025

The Stichting RegMed XB is presented on a stand-alone basis, providing a clearer view of the organisation's own income and costs.

OFFICE BALANCE SHEET
(€ x 1, as of 31 December)

	2025	2024
ASSETS		
Tangible fixed assets	42.861	53.617
Debtors	*103.861*	*0*
Prepayments and accrued income	*1.145.220*	*1.196.614*
Subtotal receivables	1.249.081	1.196.614
Cash and banks	1.976.692	1.618.937
Total assets	**3.268.634**	**2.869.169**

EQUITY AND LIABILITIES

Unappropriated reserve	244.408	0
Creditors	*21.635*	*64.317*
Taxes and social security charges	*63.294*	*47.179*
Accruals and deferred income	*2.939.297*	*2.757.673*
Subtotal current liabilities	3.024.226	2.869.168
Total equity and liabilities	**3.268.634**	**2.869.168**

EXPENSES



	2025	2024
Management	431.524	550.313
Project	472.828	426.031
Office	265.981	207.773
Marketing & com.	239.770	208.401
Audit & adm.	212.327	289.607
Governance	78.285	345.141
Total expenses	**1.700.715**	**2.027.266**

INCOME

	2025	2024
Grant	460.147	405.114
General office/support	1.484.976	1.622.152
Total income	**1.945.123**	**2.027.266**

Unappropriated result **€244.408** 2024: €0

Governance Stichting RegMed XB

In 2025 two councils were established to strengthen the involvement of partners and independent experts in the organisation's direction: the Partner Council, a newly established body bringing together decision-makers from RegMed XB's partner organisations, and the Expert Council, which succeeded the former Scientific Advisory Board to provide scientific and strategic expertise in the further development of regenerative medicine products. Both councils became operational during 2025, alongside the existing Supervisory Board and Management Team.



PARTNER COUNCIL

- Leiden University Medical Centre
- Utrecht University/UMCU Medical Center Utrecht
- Maastricht University/Maastricht UMC+
- Eindhoven University of Technology
- Nierstichting Nederland
- Stichting Reuma Nederland
- De Nederlandse Hartstichting
- Diabetes Fonds
- Oogfonds
- RegMed XB vzw

SUPERVISORY BOARD

- Conny Helder (Chair)
- Koenraad Debackere
- Maurice Horsten
- Arno van Son
- Floris Italianer

EXECUTIVE BOARD & MANAGEMENT TEAM

- Bernard Mulder (CEO)
- Frank Luyten
- Tom Oostrom (non-exec)
- Erik Eijrond
- Bart Geers
- Olaf Geurts

EXPERT COUNCIL

- Nico Stam (Chair)
- Prof. Dr. Philippe Menasché
- Prof. Dr. Katja Schenke-Layland
- Prof. Dr. Thierry Berney
- Prof. Alicia El Haj
- Prof. Dr. Caroline Klaver
- Prof. Dr. Nine Knoers
- Dr. Frans van Andel
- Stef C. Schutte
- Prof. Dr. Maurilio Sampaolesi

Looking ahead

Research Excellence

- €2 million Public-Private Partnerships funding annually through 2027
- Development of five Moonshots

Business Development

- Thematic Tech Transfer (TTT) programme (2025-2030) fully operational
- Expanded scouting capacity

Infrastructure

- New Moonshots in Pilot Factory
- Increased manufacturing readiness

Internationalisation

- European ATMP Centre of Excellence ambition
- More Dutch-Japanese collaboration

Upcoming Events

RegMed XB-DCVA Event

3 November 2026

Joint event to connect, share and accelerate.



Annual Conference

23 – 24 June 2027

Two days of insights, innovation and international collaboration.

Thanks to all

Health Foundations

Diabetes Fonds
don
Hartstichting
Hersen Stichting
NIER Stichting
Oogfonds
ReumaNederland

Pilot Factory pilot lines

ICAT
Leids Universitair Medisch Centrum
NecstGen a non-profit CDMO
ReGEN Biomedical
SBMC Smart BioMaterials Center

Industrial partners

Access2bone
AXION BIOSYSTEMS
CiMaas
Coagulation Profile
COMATE Engineering & Design
ETB-BISLIFE
eurobiogendx
FUJIFILM VISUALSONICS
HCM Medical
interflow
Kuros Biosciences
LifeTec Group A RESOLUTION MEDICAL COMPANY
Medace
MIMETAS
Ncardia Stem cell experts
NTrans Technologies
QUALITY ASSISTANCE Contract Research Organisation
Rousselot by Darling Ingredients
scannexus
SCINUS CELL EXPANSION
SINGLE CELL DISCOVERIES
Starfish INNOVATIONS
STENTIT
SupraPolix
U-CyTech biosciences
veldlaser
XELTIS
300MICRONS

Academic partners

GHENT UNIVERSITY
KU LEUVEN
Leids Universitair Medisch Centrum
Maastricht University
Maastricht UMC+
TU/e EINDHOVEN UNIVERSITY OF TECHNOLOGY
University of Antwerp
UMC Utrecht
Utrecht University
VIB
VUB VRIJE UNIVERSITEIT BRUSSEL

Governmental partners

Health/Holland
WEWIS Department of Work Economy, Science Innovation & Social Economy
provincie limburg
Provincie Noord-Brabant
PROVINCIE UTRECHT
provincie Zuid-Holland
Ministerie van Economische Zaken en Klimaat
Ministerie van Volksgezondheid, Welzijn en Sport
Ministerie van Onderwijs, Cultuur en Wetenschap
Netherlands Enterprise Agency
Government of the Netherlands | This project is supported by the National Growth fund
Flanders State of the Art

Life Science & Health partners

biotech booster
health RI
HOLOmicrobiome
Inserm
NQ Qross
NXT GEN hightech
ombion Centre for Animal-free Biomedical Translation
Oncode Accelerator
PharmaNL
Interreg ATMP XB
JSRM

Valorisation partners

BGV.
Dutch CardioVascular Alliance
First.